I have received the following letter from the company in regards to its week of March 18th data release on its schizophrenia drug in Phase II/III. “Dear Scott, Thank you for approaching us with your clarification questions. The independent Data…
Month: January 2013
BioLineRx: Big Catalyst Upcoming With Potential Multi Billion Dollar Schizophrenia Drug
BioLineRx’s (BLRX) engages in identifying, in-licensing, and developing therapeutic candidates. Its lead clinical therapeutic candidate under development is BL-1020, which is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients. BL-1020 is an orally available, first in…
Legendary Icahn Still Slugging Away With Enzon Pharma
Carl C. Icahn has been the principal beneficial shareholder of Icahn Enterprises L.P. (NYSE: IEP) and has served as Chairman of the board, a director, and an owner of the company’s general partner since 1990. Mr. Icahn heads the investment…
Tuesday’s Small Cap Biopharma Investment And Catalyst Trade List
At Stockmatusow.com, my team of traders and investors scan the biotech sector daily, looking for stocks we believe provide excellent trading and investment opportunities. We factor in potential price moving catalyst events along with chart technicals and current news events,…
EDAP: An Undervalued Company With An Alternative Treatment For Prostate Cancer
In doing some fresh scans for 2013, I found a company that has a very small market cap of only $38 million but competes in the very large market of prostate cancer. EDAP TMS SA (EDAP) looks like a very…